Literature DB >> 1659268

Leukotrienes C4, D4, and E4 enhance histamine responsiveness in asthmatic airways.

S P O'Hickey1, R J Hawksworth, C Y Fong, J P Arm, B W Spur, T H Lee.   

Abstract

The effects of prior inhalation of each of the sulfidopeptide leukotrienes (LT), LTC4, LTD4, and LTE4 on airway responsiveness to histamine have been compared in seven asthmatic and six normal subjects. Each subject underwent histamine inhalation challenge at 1, 4, and 7 h after inhalation of phosphate-buffered saline and bronchoconstricting doses of LTC4, LTD4, LTE4, and methacholine, which produced a greater than 30% fall in specific airway conductance. In asthmatic subjects, prior inhalation of LTC4, LTD4, and LTE4 enhanced airway responsiveness to histamine when compared with saline inhalation, on average by a maximum of 3.9-, 2.8-, and 3.1-fold, respectively, at 4 h after inhalation. Methacholine inhalation did not significantly after histamine responsiveness throughout the time course studied. In normal subjects, inhalation of LTC4, LTD4, LTE4, and methacholine did not change airway responsiveness to histamine. Thus, LTC4 and LTD4 were similar to LTE4 in their capacity to enhance airway responsiveness to histamine in asthmatic subjects, and, in common with LTE4, they failed to elicit a change in airway responsiveness to histamine in normal subjects.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1659268     DOI: 10.1164/ajrccm/144.5.1053

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  21 in total

Review 1.  Antileukotrienes and laboratory models of asthma.

Authors:  S C Lazarus
Journal:  Clin Rev Allergy Immunol       Date:  1999 Spring-Summer       Impact factor: 8.667

Review 2.  Biochemistry and physiology of the leukotrienes.

Authors:  N C Barnes; L J Smith
Journal:  Clin Rev Allergy Immunol       Date:  1999 Spring-Summer       Impact factor: 8.667

Review 3.  Pharmacotherapy and airway remodelling in asthma?

Authors:  P A Beckett; P H Howarth
Journal:  Thorax       Date:  2003-02       Impact factor: 9.139

4.  Effect of a 5-lipoxygenase inhibitor and leukotriene antagonist (PF 5901) on PAF-induced airway responses in neonatally immunized rabbits.

Authors:  C M Herd; D Donigi-Gale; T S Shoupe; C P Page
Journal:  Br J Pharmacol       Date:  1992-12       Impact factor: 8.739

Review 5.  Pharmacological inhibition of leukotriene actions.

Authors:  F Engels; F P Nijkamp
Journal:  Pharm World Sci       Date:  1998-04

6.  Leukotriene C(4) enhances the contraction of porcine tracheal smooth muscle through the activation of Y-27632, a rho kinase inhibitor, sensitive pathway.

Authors:  H Setoguchi; J Nishimura; K Hirano; S Takahashi; H Kanaide
Journal:  Br J Pharmacol       Date:  2001-01       Impact factor: 8.739

Review 7.  Zafirlukast. A review of its pharmacology and therapeutic potential in the management of asthma.

Authors:  J C Adkins; R N Brogden
Journal:  Drugs       Date:  1998-01       Impact factor: 9.546

Review 8.  Childhood asthma: causes, epidemiological factors and complications.

Authors:  D J Valacer
Journal:  Drugs       Date:  2000       Impact factor: 9.546

9.  Effect of a 5-lipoxygenase inhibitor and leukotriene antagonist (PF 5901) on antigen-induced airway responses in neonatally immunized rabbits.

Authors:  C M Herd; D Donigi-Gale; T S Shoupe; D A Burroughs; M Yeadon; C P Page
Journal:  Br J Pharmacol       Date:  1994-05       Impact factor: 8.739

10.  Effect of the 5-lipoxygenase inhibitor ZD2138 on allergen-induced early and late asthmatic responses.

Authors:  S M Nasser; G S Bell; R J Hawksworth; K E Spruce; R MacMillan; A J Williams; T H Lee; J P Arm
Journal:  Thorax       Date:  1994-08       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.